Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 4/20 | 0.56 |
| ▸ | DRD3 | P35462 | 4/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 5/20 | 0.53 |
| ▸ | HTR7 | P34969 | 5/20 | 0.53 |
| ▸ | HTR6 | P50406 | 5/20 | 0.53 |
| ▸ | HTR1A | P08908 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385162 | 0.99 | DRD2 (0.57) | DRD2CHRM1KCNH2DRD4DRD3 | |
| SCHEMBL5380399 | 0.98 | DRD2 (0.60) | DRD2CHRM1KCNH2DRD4DRD3 | |
| SCHEMBL5387903 | 0.89 | HTR1A (0.66) | DRD2CHRM1KCNH2DRD4DRD3 | |
| SCHEMBL5389417 | 0.89 | HTR1A (0.65) | DRD2CHRM1KCNH2DRD4DRD3 | |
| SCHEMBL5396144 | 0.88 | HTR1A (0.66) | DRD2CHRM1KCNH2DRD4DRD3 | |
| SCHEMBL5386750 | 0.86 | OPRM1 (0.55) | DRD2CHRM1KCNH2DRD4OPRM1 | |
| SCHEMBL5392528 | 0.84 | OPRM1 (0.58) | OPRM1OPRK1OPRL1HTR2AHTR7 | |
| SCHEMBL5389629 | 0.84 | SLC6A4 (0.65) | DRD2CHRM1KCNH2OPRM1OPRK1 | |
| SCHEMBL5392499 | 0.83 | OPRM1 (0.57) | OPRM1OPRK1OPRL1HTR2AHTR7 | |
| SCHEMBL5396316 | 0.83 | DRD2 (0.57) | DRD2CHRM1KCNH2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294710-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2005-06-08 | — | — | EP | claimed |
| US-6890916-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-05-10 | — | — | US | claimed |
| EP-1468996-A1 | Indole derivatives for the treatment of CNS disorders | H. Lundbeck A/S (DK) | 2004-10-20 | — | — | EP | claimed |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-10-09 | — | — | US | claimed |
| EP-1294710-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-03-26 | — | — | EP | claimed |
| WO-2001096328-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2001-12-20 | — | — | WO | claimed |
| US-7276508-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2007-10-02 | — | — | US | disclosed |
| EP-1468996-B1 | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2007-09-26 | — | — | EP | disclosed |
| US-20050176729-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| EP-1294710-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-6890916-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-05-10 | — | — | US | disclosed |
| EP-1468996-A1 | Indole derivatives for the treatment of CNS disorders | H. Lundbeck A/S (DK) | 2004-10-20 | — | — | EP | disclosed |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-10-09 | — | — | US | disclosed |
| EP-1294710-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096328-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176729-A1 | Indole derivatives useful for the treatment of CNS disorders | HTR4, TPH1, SLC6A3 | DRD2 14/4885CHRM1 69/4885KCNH2 1136/4885 |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | TPH1, CHRM1, TPH2 | DRD2 47/4885CHRM1 2/4885KCNH2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.